Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
$200.00
In an announcement that came as a surprise to industry experts, Scott Gottlieb announced his resignation as head of the US FDA after only a 22-month tenure. See what his legacy will be, and what his departure means for pilot projects currently in the works.
Publisher: MedTech
- Description
Scott Gottlieb’s surprise March 5 announcement that he would be stepping down from his role as US FDA Commissioner took industry insiders by surprise. Take a look back at Gottlieb’s accomplishments during his brief, 22-month tenure in the position, find out what’s next for the agency, and discover what his departure means for several major initiatives currently in the pilot phase, as Medtech Insight takes you behind the headlines and into the impact of the news affecting the medtech industry.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
EMA Issues Guidance On Medical Devices That Are Integral To Pharma Products 
Sign up to the